- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Trump Announces Reduced Drug Pricing Deal With Amgen, Gilead And Other Pharma Firms | 21 | Forbes | ||
| Fr | Amgen vereinbart mit US-Regierung niedrigere Medikamentenpreise | 6 | Investing.com Deutsch | ||
| Fr | Amgen takes action with U.S. government to lower medicine costs | 5 | Investing.com | ||
| Fr | Amgen Takes Action With The U.S. Government To Lower The Cost Of Medicines For American Patients | 111 | PR Newswire | Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing
THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN)... ► Artikel lesen | |
| Do | Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug | 18 | Benzinga.com | ||
| Mi | HSBC Turns More Bullish on Amgen (AMGN) into 2026 | 9 | Insider Monkey | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| Mi | AMGEN INC steht still - ich sehe hier eine tickende Chance! | 10 | Maximilian Berger | ||
| Mi | Amgen: Oppenheimer bestätigt "Outperform"-Rating mit Kursziel von 380 US-Dollar | 7 | Investing.com Deutsch | ||
| Mi | Amgen stock rating maintained by Oppenheimer with price target of $380 | 7 | Investing.com | ||
| 13.12. | Amgen CDR (CAD Hedged): Amgen CDR (CAD Hedged) declares dividend | 15 | Stockwatch | ||
| 12.12. | FDA Approves Amgen's Drug For Rare Muscle Disorder | 3 | Benzinga.com | ||
| 12.12. | Amgen's Uplizna breaks into crowded myasthenia gravis market with FDA nod | 4 | FiercePharma | ||
| 12.12. | Amgen granted FDA nod for Uplizna in myasthenia gravis | 2 | Seeking Alpha | ||
| 12.12. | Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis | 2 | Zacks | ||
| 12.12. | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | 340 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| 12.12. | Amgen CDR (CAD Hedged): Amgen CDR (CAD Hedged) estimates dividend | 7 | Stockwatch | ||
| 12.12. | FDA Approves Amgen's UPLIZNA For Adults With Generalized Myasthenia Gravis | 385 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG)... ► Artikel lesen | |
| 12.12. | FDA approves Amgen's UPLIZNA for generalized myasthenia gravis | 5 | Investing.com | ||
| 12.12. | Amgen: FDA Approves Uplizna For Adults With Generalized Myasthenia Gravis | 335 | PR Newswire | UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*
First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK... ► Artikel lesen | |
| 11.12. | Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx | 7 | FiercePharma |
1 2 3 4 5 Weiter >>
319 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,52 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 4,360 | -3,11 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | +3,55 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
AMGEN INC CDR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-0,68 %) liegt der Kurs bei 14,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.